← SynDRA

DABRAFENIB

SynDRA canonical compound SYN0029186 — structure-anchored drug synonym record

All known targets

• BRAF
• RAF1
• LIMK1
• ULK3
• YES1
• LIMK2
• LYN
• MAP2K5
• MAP3K11
• MELK
• MET
• NEK1

Mechanisms of action (all sources)

• RAF inhibitor
• BRAF INHIBITOR
• Serine/threonine-protein kinase B-raf inhibitor

Drug classes

• Protein Kinase Inhibitors
• Antineoplastic Agents
• Enzyme Inhibitors
• Kinase Inhibitor
• Cytochrome P450 3A4 Inducers
• Cytochrome P450 2C9 Inducers
• Cytochrome P450 2C19 Inducers
• Cytochrome P450 2C8 Inducers
• Cytochrome P450 2B6 Inducers
• Organic Anion Transporting Polypeptide 1B1 Inhibitors
• Organic Anion Transporting Polypeptide 1B3 Inhibitors
• Organic Anion Transporter 1 Inhibitors

ATC classes

• L01E · PROTEIN KINASE INHIBITORS

Cross-references

• PubChem CID: 44462760
• ChEMBL: CHEMBL2028663
• DrugBank: DB08912
• ChEBI: CHEBI:75045
• KEGG: D10064
• RxNorm: 1424911
• PDB: P06
• Wikipedia: Dabrafenib
• TTD: D05ROI
• LINCS BRD: BRD-K09951645

Synonyms

• GSK2118436B
• dabrafenib mesylate
• tafinlar
• GSK2118436
• dabrafenib mesilate
• Gsk2118436
• GSK-2118436
• GSK-2118436A
• GSK2118436A
• Tafinlar
• Dabrafenib (GSK2118436)
• UNII-QGP4HA4G1B
• GSK 2118436
• QGP4HA4G1B
• N-(3-(5-(2-aminopyrimidin-4-yl)-2-tert-butylthiazol-4-yl)-2-fluorophenyl)-2,6-difluorobenzenesulfonamide
• CHEBI:75045
• N-[3-[5-(2-Amino-4-pyrimidinyl)-2-(tert-butyl)-4-thiazolyl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide
• N-{3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide
• Dabrafenib [USAN:INN]
• GSK 2118436A
• 1195765-45-7 (free base)
• Dabrafenib (USAN)
• N-(3-(5-(2-aminopyrimidin-4-yl)-2-(tert-butyl)thiazol-4-yl)-2-fluorophenyl)-2,6-difluorobenzenesulfonamide
• N-[3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide
• DABRAFENIB [USAN]
• Dabrafenib (Free Base)
• BENZENESULFONAMIDE, N-(3-(5-(2-AMINO-4-PYRIMIDINYL)-2-(1,1-DIMETHYLETHYL)-4-THIAZOLYL)-2-FLUOROPHENYL)-2,6-DIFLUORO-
• Benzenesulfonamide, N-[3-[5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl]-2-fluorophenyl]-2,6-difluoro-
• N-(3-(5-(2-AMINOPYRIMIDIN-4-YL)-2-TERT-BUTYL-1,3-THIAZOL-4-YL)-2-FLUOROPHENYL)-2,6-DIFLUOROBENZENESULFONAMIDE
• N-{3-[5-(2-aminopyrimidin-4-yl)-2-tert-butylthiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide
• P06
• DABRAFENIB [MI]
• DABRAFENIB [INN]
• DABRAFENIB [VANDF]
• DABRAFENIB [WHO-DD]
• MLS006011052
• SCHEMBL806377
• GTPL6494

Reported adverse events

• Abdominal pain
• Alopecia
• Anxiety
• Arthralgia
• Atrioventricular block
• Atrioventricular block complete
• Back pain
• Cardiomyopathy
• Chills
• Colitis
• Constipation
• Cough